Arms |
Assigned Interventions |
Experimental:P1a Arm A (Monotherapy Dose Escalation).
COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
|
Drug:COM701 COM701 monotherapy. |
Experimental:P1a Arm B (Combination Dose Escalation).
COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
|
Drug:COM701 with Opdivo (Nivolumab). COM701 in combination with Opdivo (Nivolumab). |
Experimental:P1a Arm A (Monotherapy Expansion).
COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
|
Experimental:P1b (Combination Cohort Dose Expansion).
COM701 administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial cancer and Colorectal cancer).
|